HDM3001 (PRV-3279)
Systemic Lupus Erythematosus (SLE)
Phase IIActive
Key Facts
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Phase II
Status
Active
About Huadong Medicine (HD Medicine)
Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| nipocalimab | Johnson and Johnson Innovative Medicine | Phase 3 |
| IFNα Kinoid® (IFNa-K) | Neovacs | Phase 2 |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Cenerimod | Ono Pharmaceutical | Phase 3 |
| Efgartigimod | Argenx | Phase 3 |